These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 35997567)
41. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229 [TBL] [Abstract][Full Text] [Related]
42. International definition of iMCD-TAFRO: future perspectives. Nishimura Y; Nishimura MF; Sato Y J Clin Exp Hematop; 2022 Jun; 62(2):73-78. PubMed ID: 35474036 [TBL] [Abstract][Full Text] [Related]
43. Candidate biomarkers for idiopathic multicentric Castleman disease. Sumiyoshi R; Koga T; Kawakami A J Clin Exp Hematop; 2022; 62(2):85-90. PubMed ID: 35768241 [TBL] [Abstract][Full Text] [Related]
44. Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman disease. Montes-Moreno S; Climent F; Fraga M; Luis Patier J; Robles-Marhuenda Á; García-Sanz R; Ocio EM; González García A; Navarro JT Rev Esp Patol; 2023; 56(3):158-167. PubMed ID: 37419554 [TBL] [Abstract][Full Text] [Related]
45. Evolution of Pulmonary Involvement in Idiopathic Multicentric Castleman Disease-Not Otherwise Specified: From Nodules to Cysts or Consolidation. Zhou J; Zhang L; Liu X; Zhang M; Li J; Zhang W Chest; 2023 Aug; 164(2):418-428. PubMed ID: 36963752 [TBL] [Abstract][Full Text] [Related]
46. The Cytokine Storm of Multicentric Castleman Disease. Fajgenbaum DC Adv Exp Med Biol; 2024; 1448():459-467. PubMed ID: 39117833 [TBL] [Abstract][Full Text] [Related]
47. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567 [TBL] [Abstract][Full Text] [Related]
49. Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease. Terasaki Y; Ikushima S; Matsui S; Hebisawa A; Ichimura Y; Izumi S; Ujita M; Arita M; Tomii K; Komase Y; Owan I; Kawamura T; Matsuzawa Y; Murakami M; Ishimoto H; Kimura H; Bando M; Nishimoto N; Kawabata Y; Fukuda Y; Ogura T; Histopathology; 2017 Jun; 70(7):1114-1124. PubMed ID: 28207938 [TBL] [Abstract][Full Text] [Related]
50. Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28 cases. Kojima M; Nakamura N; Tsukamoto N; Otuski Y; Shimizu K; Itoh H; Kobayashi S; Kobayashi H; Murase T; Masawa N; Kashimura M; Nakamura S Int J Surg Pathol; 2008 Oct; 16(4):391-8. PubMed ID: 18499694 [TBL] [Abstract][Full Text] [Related]
51. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports. Ferrero S; Ragaini S J Med Case Rep; 2021 Mar; 15(1):105. PubMed ID: 33676575 [TBL] [Abstract][Full Text] [Related]
52. Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease. Nishikori A; Nishimura MF; Fajgenbaum DC; Nishimura Y; Maehama K; Haratake T; Tabata T; Kawano M; Nakamura N; Momose S; Sumiyoshi R; Koga T; Yamamoto H; van Rhee F; Kawakami A; Sato Y J Clin Pathol; 2024 Feb; ():. PubMed ID: 38378248 [TBL] [Abstract][Full Text] [Related]
53. Pulmonary Manifestations of Plasma Cell Type Idiopathic Multicentric Castleman Disease: A Clinicopathological Study in Comparison with IgG4-Related Disease. Nishimura MF; Igawa T; Gion Y; Tomita S; Inoue D; Izumozaki A; Ubara Y; Nishimura Y; Yoshino T; Sato Y J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33321725 [TBL] [Abstract][Full Text] [Related]
54. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab. Furutera N; Fukunaga N; Okita J; Suzuki T; Suenaga Y; Oyama Y; Aoki K; Fukuda A; Nakata T; Uesugi N; Daa T; Hisano S; Shibata H CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375 [TBL] [Abstract][Full Text] [Related]
55. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459 [TBL] [Abstract][Full Text] [Related]
56. Idiopathic Multicentric Castleman Disease with Strikingly Elevated IgG4 Concentration in the Serum and Abundant IgG4-Positive Cells in the Tissue: A Case Report. Cheng CC; Chen YC; Hsu YH; Su KY Diagnostics (Basel); 2022 Sep; 12(9):. PubMed ID: 36140662 [TBL] [Abstract][Full Text] [Related]
57. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. Dong Y; Zhang L; Nong L; Wang L; Liang Z; Zhou D; Fajgenbaum DC; Ren H; Li J Ann Hematol; 2018 Sep; 97(9):1641-1647. PubMed ID: 29732477 [TBL] [Abstract][Full Text] [Related]